Investor Relations

IR Home

Recent Newsmore >
06/20/17
ConforMIS Announces FDA 510(k) Clearance for iTotal Hip System
New hip replacement implant system builds on ConforMIS’s customized knee replacement technology and positions Company to expand in global orthopedics market BILLERICA, Mass., June 20, 2017 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that offers knee replacement implants customized to fit each patient's unique anatomy, today announced it has received FDA 510(k) clearance of the Company’s primary iTotal Hip replacement system. ... 
06/13/17
ConforMIS Announces the Publication of Clinical and Economic Study Comparing Customized Total Knee Replacement Implants to Off-the-Shelf Total Knee Replacement Implants
Data published in Arthroplasty Today demonstrate that patients treated with customized knee implants had significantly lower adverse event rates and transfusion rates, were significantly less likely to be discharged to a rehabilitation or other high-cost post-acute care facilities, had a lower average total cost of the episode of care and had a significantly lower average cost of follow-up care. BILLERICA, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical techn... 
Upcoming Eventsmore >
There are currently no events scheduled.
IR Contact
Oksana Bradley
Investor Relations
Phone: (781) 374-5598
E-mail: ir@conformis.com

Media Contacts
Bill Berry
Berry & Company Public Relations
Phone: (212) 253-8881
E-mail: Bberry@berrypr.com

Lynn Granito
Berry & Company Public Relations
Phone: (212) 253-8881
E-mail: Lgranito@berrypr.com
Featured Reports
There are currently no items available.
Data provided by Nasdaq. Minimum 15 minutes delayed.